We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Product News   May 28, 2020

 
IRBM’s Advent Manufactures 13,000 Doses of COVID-19 Vaccine for Use in Phase 2/3 Clinical Trials

Credit: Pixabay

FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Intravacc to In-license CimCure’s iBoost Technology

Product News

Intravacc has announced the signing of a strategic partnership agreement with Dutch-based CimCure for in-licensing CimCure’s iBoost technology.

READ MORE

Kerafast Offers the Delta-G-VSV Pseudotyping System for Coronavirus Research

Product News

Kerafast Inc. has announced the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications, enabling studies of SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 containment.

READ MORE

Vaccine Against COVID-19 Advances to Late-stage Development

Product News

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced progress on late-stage development of mRNA-1273, the Company’s mRNA vaccine candidate against COVID-19.

READ MORE

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE